JP2005319305A - 磁気共鳴スペクトロスコピーを用いて神経変性疾患を検出及び監視するための方法及びシステム - Google Patents
磁気共鳴スペクトロスコピーを用いて神経変性疾患を検出及び監視するための方法及びシステム Download PDFInfo
- Publication number
- JP2005319305A JP2005319305A JP2005135528A JP2005135528A JP2005319305A JP 2005319305 A JP2005319305 A JP 2005319305A JP 2005135528 A JP2005135528 A JP 2005135528A JP 2005135528 A JP2005135528 A JP 2005135528A JP 2005319305 A JP2005319305 A JP 2005319305A
- Authority
- JP
- Japan
- Prior art keywords
- metabolite
- data
- neurodegenerative disease
- magnetic resonance
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 66
- 230000004770 neurodegeneration Effects 0.000 title claims abstract description 43
- 208000015122 neurodegenerative disease Diseases 0.000 title claims abstract description 43
- 238000004611 spectroscopical analysis Methods 0.000 title claims abstract description 25
- 238000012544 monitoring process Methods 0.000 title claims abstract description 11
- 239000002207 metabolite Substances 0.000 claims abstract description 68
- 230000003595 spectral effect Effects 0.000 claims abstract description 34
- 230000035945 sensitivity Effects 0.000 claims abstract description 15
- 238000001228 spectrum Methods 0.000 claims abstract description 14
- 210000004556 brain Anatomy 0.000 claims abstract description 11
- 238000013480 data collection Methods 0.000 claims abstract description 9
- 238000011002 quantification Methods 0.000 claims abstract description 8
- 238000003384 imaging method Methods 0.000 claims abstract description 6
- OTCCIMWXFLJLIA-BYPYZUCNSA-N N-acetyl-L-aspartic acid Chemical compound CC(=O)N[C@H](C(O)=O)CC(O)=O OTCCIMWXFLJLIA-BYPYZUCNSA-N 0.000 claims description 44
- OTCCIMWXFLJLIA-UHFFFAOYSA-N N-acetyl-DL-aspartic acid Natural products CC(=O)NC(C(O)=O)CC(O)=O OTCCIMWXFLJLIA-UHFFFAOYSA-N 0.000 claims description 43
- 201000010099 disease Diseases 0.000 claims description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 23
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims description 18
- 208000024827 Alzheimer disease Diseases 0.000 claims description 14
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 11
- 238000001514 detection method Methods 0.000 claims description 10
- 229960003624 creatine Drugs 0.000 claims description 9
- 239000006046 creatine Substances 0.000 claims description 9
- 230000005284 excitation Effects 0.000 claims description 7
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 5
- 229930195712 glutamate Natural products 0.000 claims description 4
- 238000012805 post-processing Methods 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 3
- 230000008569 process Effects 0.000 abstract description 7
- 238000012545 processing Methods 0.000 description 14
- 210000003484 anatomy Anatomy 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 5
- 238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000003321 amplification Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 208000009989 Posterior Leukoencephalopathy Syndrome Diseases 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000004326 gyrus cinguli Anatomy 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 230000005415 magnetization Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 230000007991 neuronal integrity Effects 0.000 description 1
- 238000010855 neuropsychological testing Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 238000012306 spectroscopic technique Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/46—NMR spectroscopy
- G01R33/465—NMR spectroscopy applied to biological material, e.g. in vitro testing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
- A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
- A61B5/4088—Diagnosing of monitoring cognitive diseases, e.g. Alzheimer, prion diseases or dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Physics & Mathematics (AREA)
- High Energy & Nuclear Physics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Microbiology (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Analytical Chemistry (AREA)
- Radiology & Medical Imaging (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Abstract
【解決手段】神経変性疾患を検出する磁気共鳴スペクトロスコピー撮像技法の感度及び/または特異度を増大させるための方法を提供する。本方法は、残留する代謝産物の定量化確度を向上させるためにスペクトル内のある種の代謝産物をデータ収集プロトコルを介して抑制しながら対象(100)の脳から磁気共鳴スペクトロスコピー・データを収集する工程と、このスペクトル・データからの代謝産物濃度または代謝産物濃度比を神経変性疾患の指標として定量化する工程と、を含む。
【選択図】 図5
Description
86 ROC曲線
88 磁気共鳴スペクトロスコピー・システム
90 マグネット・アセンブリ
92 制御/収集回路
94 システム制御装置
96 オペレータ・インタフェース・ステーション
98 関心領域
100 対象
102 主コイル
104 傾斜コイル・アセンブリ
106 RF送信/受信コイル
108 テーブル
110 信号処理回路
112 コイル制御回路
114 インタフェース回路
116 中央処理回路
118 メモリ回路
120 インタフェース回路
122 入力デバイス
124 ディスプレイ、出力デバイス
Claims (9)
- 神経変性疾患の検出に関する磁気共鳴スペクトロスコピー撮像技法の感度及び/または特異度を増大させるための方法であって、
スペクトル内の共鳴を抑制するデータ収集技法を用いることによってスペクトル内の関心対象の代謝産物からのスペクトル・ピークを維持しながら対象(100)の脳から磁気共鳴スペクトロスコピー・データを収集する工程と、
スペクトル内に存在する複数の代謝産物の濃度または濃度比を定量化する工程と、
前記関心対象の代謝産物の濃度または濃度比を神経変性疾患の指標として使用する工程と、
を含む方法。 - 前記データ収集技法はPRESS−Jである、請求項1に記載の方法。
- 神経変性疾患の初期段階を特定する工程をさらに含む請求項1に記載の方法。
- 有志の健常被験者と神経変性疾患であると診断された患者について前記関心対象の代謝産物の濃度または濃度比を比較する工程をさらに含む請求項1に記載の方法。
- スペクトル内において抑制された前記共鳴がグルタメート及びグルタミンに属するものである、請求項1に記載の方法。
- 少なくともN−アセチルアスパラギン酸及び/またはN−アセチルアスパラギン酸/クレアチンの代謝産物濃度または代謝産物比に関する経時的な変化を検出することによって、神経変性疾患であると診断された患者の疾患あるいは該疾患の処置に対する監視を支援する工程をさらに含む請求項1に記載の方法。
- 前記神経変性疾患がアルツハイマー病である、請求項1に記載の方法。
- 制御式の傾斜磁場を発生させるための1組の傾斜コイル(104)と、
関心対象に励起信号を印加するための無線周波数コイル(106)と、
励起信号に起因する磁気共鳴信号を検出するための検出コイル(106)と、
前記1組の傾斜コイル及びRFコイルを付勢させて磁気共鳴スペクトロスコピー・データを収集するように構成された制御/収集回路(92)であって、関心対象の代謝産物に関するデータ定量化確度を向上させるためにデータ収集プロトコルを介してスペクトル・データ内で共鳴が抑制される制御/収集回路(92)と、
収集された磁気共鳴スペクトロスコピー・データから代謝産物差異を有する画像を取得するように構成されたシステム制御装置回路(94)と、
前記スペクトル・データから少なくともN−アセチルアスパラギン酸及び/またはN−アセチルアスパラギン酸/クレアチンに関する代謝産物濃度または代謝産物濃度比を神経変性疾患の指標として定量化するように構成された後処理用構成要素(116)と、
を備えるMRスペクトロスコピー・システム(88)。 - 神経変性疾患を診断しかつ処置するためのコンピュータ命令を保存するためのコンピュータ読み取り可能媒体であって、該コンピュータ命令は、
関心対象の代謝産物に関する定量化確度を向上させるために、スペクトル内の共鳴を抑制しながら対象の脳から磁気共鳴スペクトロスコピー・データを収集させる命令と、
前記スペクトル・データから少なくともN−アセチルアスパラギン酸及び/またはN−アセチルアスパラギン酸/クレアチンに関する代謝産物濃度または代謝産物濃度比を神経変性疾患の指標として定量化させる命令と、
を含んでいる、コンピュータ読み取り可能媒体。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56957304P | 2004-05-10 | 2004-05-10 | |
US11/072,831 US7742800B2 (en) | 2004-05-10 | 2005-03-04 | Methods and systems for detection and monitoring of neurodegenerative diseases using magnetic resonance spectroscopy |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2005319305A true JP2005319305A (ja) | 2005-11-17 |
Family
ID=35240319
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005135528A Pending JP2005319305A (ja) | 2004-05-10 | 2005-05-09 | 磁気共鳴スペクトロスコピーを用いて神経変性疾患を検出及び監視するための方法及びシステム |
Country Status (4)
Country | Link |
---|---|
US (1) | US7742800B2 (ja) |
JP (1) | JP2005319305A (ja) |
DE (1) | DE102005021401A1 (ja) |
NL (1) | NL1029000C2 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008237747A (ja) * | 2007-03-28 | 2008-10-09 | Dainippon Printing Co Ltd | 関心領域決定装置 |
JP2010110567A (ja) * | 2008-11-10 | 2010-05-20 | Hitachi Medical Corp | 磁気共鳴イメージング装置 |
JP2010529868A (ja) * | 2007-05-17 | 2010-09-02 | ゼネラル・エレクトリック・カンパニイ | 過分極13c−ピルビン酸塩を含むmr造影剤を用いて腫瘍のグレーディングを行うmr方法 |
KR101086352B1 (ko) | 2009-06-12 | 2011-11-23 | 세종대학교산학협력단 | Hsqc nmr을 이용한 대사물질 정량 분석 방법 |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100016706A1 (en) * | 2006-12-08 | 2010-01-21 | Molecular Image, Inc. | Methods for diagnosis and monitoring of neurologic diseases using magnetic resonance methods |
BRPI0806785A2 (pt) * | 2007-01-30 | 2011-09-13 | Ge Healthcare Ltd | ferramentas para auxiliar no diagnóstico de doenças neurodegenerativas |
US7805421B2 (en) * | 2007-11-02 | 2010-09-28 | Caterpillar Inc | Method and system for reducing a data set |
US8761860B2 (en) * | 2009-10-14 | 2014-06-24 | Nocimed, Llc | MR spectroscopy system and method for diagnosing painful and non-painful intervertebral discs |
US8825131B2 (en) * | 2009-10-14 | 2014-09-02 | Nocimed, Llc | MR spectroscopy system and method for diagnosing painful and non-painful intervertebral discs |
US9280718B2 (en) | 2010-11-24 | 2016-03-08 | Nocimed, Llc | Systems and methods for automated voxelation of regions of interest for magnetic resonance spectroscopy |
US20130190606A1 (en) * | 2012-01-25 | 2013-07-25 | Huntington Medical Research Institutes | Combined quantitative mri and quantitative mrs for diagnosis of alzheimers disease and hippocampal sclerosis |
US8965094B2 (en) | 2012-04-14 | 2015-02-24 | Nocimed, Llc | Magnetic resonance spectroscopy pulse sequence, acquisition, and processing system and method |
US20170209084A1 (en) * | 2014-05-07 | 2017-07-27 | University Of Utah Research Foundation | Diagnosis of affective disorders using magnetic resonance spectroscopy neuroimaging |
EP4289347A3 (en) | 2016-06-19 | 2024-03-06 | Aclarion, Inc. | Magnetic resonance spectroscopy system and method for diagnosing pain or infection associated with propionic acid |
EP3486674A1 (en) * | 2017-11-17 | 2019-05-22 | Koninklijke Philips N.V. | Artificial intelligence-enabled localization of anatomical landmarks |
US11894139B1 (en) * | 2018-12-03 | 2024-02-06 | Patientslikeme Llc | Disease spectrum classification |
US20220117552A1 (en) * | 2019-04-08 | 2022-04-21 | Seoul National University R&Db Foundation | Artificial neural network-based nuclear magnetic resonance and magnetic resonance spectroscopy data processing method and apparatus thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002315732A (ja) * | 2001-04-23 | 2002-10-29 | Toshiba Corp | 磁気共鳴装置及び磁気共鳴装置における信号処理方法 |
JP2004008809A (ja) * | 2003-10-02 | 2004-01-15 | Toshiba Corp | 磁気共鳴診断装置 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5617861A (en) * | 1994-02-16 | 1997-04-08 | Huntington Medical Research Institutes | Magnetic resonance spectral analysis of the brain for diagnosis of clinical conditions |
US5657757A (en) * | 1995-08-17 | 1997-08-19 | General Electric Company | Interleaved MR spectroscopy and imaging with dynamically changing acquisition parameters |
US5924987A (en) * | 1997-10-06 | 1999-07-20 | Meaney; James F. M. | Method and apparatus for magnetic resonance arteriography using contrast agents |
US6069478A (en) | 1997-11-24 | 2000-05-30 | General Electric Corporation | Magnetic resonance spectroscopic imaging having reduced parasitic side band signals |
US6104191A (en) | 1998-03-17 | 2000-08-15 | General Electric Company | Quantitative in vivo spectroscopy using oversampling, waterline referencing, and prior knowledge fitting |
US6147492A (en) * | 1998-10-28 | 2000-11-14 | Toshiba America Mri, Inc. | Quantitative MR imaging of water and fat using a quadruple-echo sequence |
US6819952B2 (en) * | 2001-03-23 | 2004-11-16 | The Board Of Trustees Of The Leland Stanford Junior University | Magnetic resonance spectroscopic imaging method to monitor progression and treatment of neurodegenerative conditions |
US6617169B2 (en) | 2001-03-30 | 2003-09-09 | Mclean Hospital Corporation | Two-dimensional MR spectroscopy techniques |
-
2005
- 2005-03-04 US US11/072,831 patent/US7742800B2/en active Active
- 2005-05-04 DE DE102005021401A patent/DE102005021401A1/de not_active Ceased
- 2005-05-09 JP JP2005135528A patent/JP2005319305A/ja active Pending
- 2005-05-10 NL NL1029000A patent/NL1029000C2/nl not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002315732A (ja) * | 2001-04-23 | 2002-10-29 | Toshiba Corp | 磁気共鳴装置及び磁気共鳴装置における信号処理方法 |
JP2004008809A (ja) * | 2003-10-02 | 2004-01-15 | Toshiba Corp | 磁気共鳴診断装置 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008237747A (ja) * | 2007-03-28 | 2008-10-09 | Dainippon Printing Co Ltd | 関心領域決定装置 |
JP2010529868A (ja) * | 2007-05-17 | 2010-09-02 | ゼネラル・エレクトリック・カンパニイ | 過分極13c−ピルビン酸塩を含むmr造影剤を用いて腫瘍のグレーディングを行うmr方法 |
JP2010110567A (ja) * | 2008-11-10 | 2010-05-20 | Hitachi Medical Corp | 磁気共鳴イメージング装置 |
KR101086352B1 (ko) | 2009-06-12 | 2011-11-23 | 세종대학교산학협력단 | Hsqc nmr을 이용한 대사물질 정량 분석 방법 |
Also Published As
Publication number | Publication date |
---|---|
DE102005021401A1 (de) | 2005-12-01 |
US7742800B2 (en) | 2010-06-22 |
US20050251025A1 (en) | 2005-11-10 |
NL1029000A1 (nl) | 2005-11-11 |
NL1029000C2 (nl) | 2007-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2005319305A (ja) | 磁気共鳴スペクトロスコピーを用いて神経変性疾患を検出及び監視するための方法及びシステム | |
By et al. | Amide proton transfer CEST of the cervical spinal cord in multiple sclerosis patients at 3T | |
Arshad et al. | Adult age differences in subcortical myelin content are consistent with protracted myelination and unrelated to diffusion tensor imaging indices | |
Mugler III et al. | Simultaneous magnetic resonance imaging of ventilation distribution and gas uptake in the human lung using hyperpolarized xenon-129 | |
US7577472B2 (en) | MRI method for producing an index indicative of brain disorders | |
Greenman et al. | Foot small muscle atrophy is present before the detection of clinical neuropathy | |
US8260397B2 (en) | Magnetic resonance method and apparatus for determining a kidney function parameter | |
Bolan | Magnetic resonance spectroscopy of the breast: current status | |
Yan et al. | Iron deposition quantification: applications in the brain and liver | |
US6819952B2 (en) | Magnetic resonance spectroscopic imaging method to monitor progression and treatment of neurodegenerative conditions | |
Foerster et al. | Multimodal MRI as a diagnostic biomarker for amyotrophic lateral sclerosis | |
Worthoff et al. | Relaxometry and quantification in simultaneously acquired single and triple quantum filtered sodium MRI | |
JP2010042257A (ja) | 灌流画像を生成する磁気共鳴方法及び装置 | |
Barisano et al. | Perivascular space imaging at ultrahigh field MR imaging | |
Bonanno et al. | Self‐gated golden angle spiral cine MRI for coronary endothelial function assessment | |
De et al. | Rapid quantitative susceptibility mapping of intracerebral hemorrhage | |
Okujava et al. | Measurement of temporal lobe T2 relaxation times using a routine diagnostic MR imaging protocol in epilepsy | |
Tomiyasu et al. | In vivo estimation of gamma‐aminobutyric acid levels in the neonatal brain | |
Dietrich et al. | Fast oxygen‐enhanced multislice imaging of the lung using parallel acquisition techniques | |
Mackowiak et al. | Motion‐resolved fat‐fraction mapping with whole‐heart free‐running multiecho GRE and pilot tone | |
Bauman et al. | Pulmonary relaxometry with inversion recovery ultra‐fast steady‐state free precession at 1.5 T | |
Fujita et al. | Estimation of gadolinium-based contrast agent concentration using quantitative synthetic MRI and its application to brain metastases: a feasibility study | |
JP4532178B2 (ja) | Mr分光法において代謝産物の信号分離を改良させた方法及び装置 | |
Starekova et al. | Improved free-breathing liver fat and iron quantification using a 2D chemical shift–encoded MRI with flip angle modulation and motion-corrected averaging | |
Jahng et al. | Double inversion recovery imaging improves the evaluation of gray matter volume losses in patients with Alzheimer’s disease and mild cognitive impairment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080507 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20101126 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20101126 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110201 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110422 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110427 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110524 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20111213 |